Finoriq research workspace
IONIS PHARMACEUTICALS INC (IONS) SEC Filings & Filing Highlights
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted. Review IONS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
- Company
- IONIS PHARMACEUTICALS INC (IONS)
- Ticker
- IONS
- Market Cap
- $8.8B
- Latest Price
- $53.12
- Industry
- Biotech & Pharma
IONIS PHARMACEUTICALS INC (IONS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for IONIS PHARMACEUTICALS INC (IONS).
| Event | Form | Date |
|---|---|---|
| TRYNGOLZA® approved by the FDA as the first and only treatment to reduce triglycerides and the...TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in pa... | 8-K8.01 | 2026-06-24 |
| TRYNGOLZA® approved by the FDA as the first and only treatment to reduce triglycerides and the...TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in pa... | 8-K7.01 | 2026-06-24 |
| Mean HFF levels returning toward baseline, after 24 months of treatment with the 80 mg dose of...On June 12, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) shared positive new data from the open-label extension study of CORE and CORE2 (“CO... | 8-K8.01 | 2026-06-12 |
| Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of DirectorsIonis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors | 8-K7.01 | 2026-06-08 |
| The Company held its virtual Annual Meeting of Stockholders on June 4, 2026. The stockholders c...The Company held its virtual Annual Meeting of Stockholders on June 4, 2026. The stockholders considered five proposals, each of which is d... | 8-K5.07 | 2026-06-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.